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HELICOBACTER PYLORI: STATE OF THE ART
Existence of any infectious agents in stomach was a big query among the microbiologists and 
gastroenterologists (1–3). Helicobacter pylori (H. pylori) is a leading cause of severe digestive 
disease, including gastric cancer (4, 5). Although over the last years, incidence of gastric carci-
noma is decreasing worldwide, it remains the fourth most common cancer and the second most 
common cause of malignancy-related death worldwide (6, 7). During the years after H. pylori 
discovery, especially following many meta-analyses and certain number of experimental evi-
dences, it became a crucial question whether there is a link between gastric cancer and H. pylori 
infection  (8). A  contributory role for H. pylori in gastric cancer was first announced by the 
International Agency for Research on Cancer (IARC), when they labeled H. pylori a class I 
carcinogen (9). Moreover, since the prevalence of H. pylori and pattern of superficial gastritis 
can change quickly within a specific population, the incidence of gastric cancer can also shift 
rapidly (10). It has been generally accepted that the risk of cancer is highest among patients 
in whom the primary colonization causes acute and then chronic inflammation (11). To our 
knowledge, certain H. pylori strains seem to differently increase the risk of cancer, depending 
on the existence of certain bacterial genotypes (for example: cagA) (12, 13). Bacterial-secreted 
CagA, inducing high levels of chronic inflammation, is the main factor increasing mutagenesis 
rate, oxidative-stress, and increased mismatch repair pathways, resulting in gastric carcinogenesis 
(14, 15). Hence, both prevalence and incidence rates are different in various geographical areas 
(16, 17). Taking together, in this paper, we aim to point out all important topics concerning 
management of H. pylori strains associated with gastric cancer.
prevention of Gastric Cancer
To now, prevention is an optimal approach to deal with gastric cancer. Thus, all choices  ending 
in elimination of the H. pylori would be on the desk. Unfortunately, we do not have any preven-
tive or therapeutic vaccine against the infection, but ongoing research is trying to find the best 
solution (18). Using metagenomic experiments can help scientists to determine properties of each 
microbiota member, which contributes in pathogenesis of gastric cancer. The molecular mechanism 
of the interaction between gastric epithelial cells and H. pylori may also suggest a novel strategy 
for effective prevention of the development of gastric cancer (19, 20). Considering genetical back-
ground bound to high risk of gastric cancer, it is a major recommendation to eradicate H. pylori 
in persons with a family history of gastric cancer (21, 22). Further studies are necessary to elucidate 
actual role of H. pylori as causative agent to the development of gastric cancer.
H. pylori and Antibiotic Resistance
Overall, H. pylori resistance to antibiotics, including clarithromycin and metronidazole, has 
increased during the last years; new therapeutic regimens are required in both national and global 
levels (23). Although a large number of therapeutic regimens are available, none had proven to be 
superior. Thus, effective country-based antibiotic therapy programs should be continued, especially 
in high prevalence regions, such as India and Iran (24–27). According to the latest Maastricht 
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Guidelines, in regions of low clarithromycin resistance (<15%), 
clarithromycin-containing treatments are recommended for 
first-line therapy (28). So far, in regions with high resistance 
to clarithromycin (>15%), the quadruple treatment, including 
bismuth, has been proposed as first-line treatment. Sequential 
therapy [non-bismuth (three antibiotics plus proton pump 
inhibitors) quadruple therapy] was recommended in the case 
of unavailability of the above therapy. The third-line therapy 
of H. pylori is another challenging topic in treatment of this 
infection. Now, most of international guidelines suggest that 
patients requiring third-line therapy should be advised to the 
antibiotic susceptibility test before prescribing. However, an 
empirical therapy (such as levofloxacin-based or furazolidone-
based therapies) can be applied if antimicrobial sensitivity data 
are not ready.
Existence of the Virulent Bacterium
H. pylori infection is thought to be acquired in early childhood 
mostly with the fecal–oral mode of transmission (29, 30). In order 
to answer how only a few among those with H. pylori infection 
develop gastric cancer, it has been proposed that there are highly 
specific strains of H. pylori, called “virulent bacterium,” carrying 
certain genotypes of cagA (1). Of interest, current knowledge 
elucidating the etiologic role of the H. pylori CagA in gastric 
cancer is lacking (31–33).
COnCLUSiOn
Gastric cancer induced by H. pylori is one of the malignancies 
associated with inflammation (34). Extensive epidemiologic 
studies showed that H. pylori eradication reduces bacterial 
effects relevant to the gastric cancer (35). The passed direction of 
H. pylori and gastric cancer research indicating on a shared line 
which should be well-established following next investigations. To 
date, existing findings indicate that gastric cancer is the biologic 
translation of carrying an infectious disease, which is interest-
ingly preventive with anti-H. pylori regimen (36, 37). Therefore, 
as an inevitable consequence, identification of H. pylori colonized 
in people with high risk of gastric cancer is the main direction of 
the future research.
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